Genmab A/S Files 6-K Report for June 2024
Ticker: GNMSF · Form: 6-K · Filed: Jun 28, 2024 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | Jun 28, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-K, registration-statement
TL;DR
Genmab filed a 6-K for June 2024, incorporating it into existing S-8 filings. Standard reporting.
AI Summary
Genmab A/S filed a Form 6-K on June 28, 2024, to report information for the month of June 2024. This filing is incorporated by reference into several of Genmab's S-8 registration statements, including File Nos. 333-232693, 333-253519, 333-262970, and 333-277273. The company's principal executive offices are located at Carl Jacobsens Vej 30, 2500 Valby, Denmark.
Why It Matters
This filing serves as an update for investors and stakeholders regarding Genmab A/S's ongoing reporting requirements with the SEC, ensuring transparency in its corporate communications.
Risk Assessment
Risk Level: low — This is a routine filing that incorporates previous information into registration statements and does not appear to contain new material financial or operational disclosures.
Key Players & Entities
- Genmab A/S (company) — Registrant
- 0001558370-24-009580 (filing_id) — Accession Number
- 20240628 (date) — Filing Date
- 333-232693 (registration_statement_id) — Incorporated by reference into S-8
- 333-253519 (registration_statement_id) — Incorporated by reference into S-8
- 333-262970 (registration_statement_id) — Incorporated by reference into S-8
- 333-277273 (registration_statement_id) — Incorporated by reference into S-8
FAQ
What is the purpose of this Form 6-K filing by Genmab A/S?
The Form 6-K is a report of a foreign private issuer filed for the month of June 2024, and it is being incorporated by reference into Genmab A/S's existing registration statements on Form S-8.
Which specific Form S-8 registration statements does this 6-K filing get incorporated into?
This 6-K filing is incorporated by reference into Genmab A/S's registration statements on Form S-8 with File Numbers 333-232693, 333-253519, 333-262970, and 333-277273.
What is the filing date of this Form 6-K?
The filing date of this Form 6-K is June 28, 2024.
Where are Genmab A/S's principal executive offices located?
Genmab A/S's principal executive offices are located at Carl Jacobsens Vej 30, 2500 Valby, Denmark.
Does this filing indicate Genmab A/S is filing an annual report under Form 20-F or 40-F?
The filing indicates that Genmab A/S files annual reports under Form 20-F, as indicated by the checkmark next to 'Form 20-F'.
Filing Stats: 231 words · 1 min read · ~1 pages · Grade level 15.4 · Accepted 2024-06-28 08:06:23
Filing Documents
- tmb-20240628x6k.htm (6-K) — 18KB
- tmb-20240628xex99d1.htm (EX-99.1) — 48KB
- tmb-20240628xex99d1001.jpg (GRAPHIC) — 5KB
- 0001558370-24-009580.txt ( ) — 74KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S's registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970 and 333-277273 ) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. nthony GENMAB A/S BY: /s/ Anthony Pagano Name: Anthony Pagano Title: Executive Vice President & Chief Financial Officer DATE: June 28, 2024 EXHIBIT INDEX O Exhibit Description of Exhibit 99.1 Company Announcement Dated June 28, 2024: Epcoritamab (TEPKINLY) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma